Mitigating payer-identified risks in cell and gene therapy development

As the case with several therapeutics, developers struggle to balance between clinical and commercial objectives. In a recent webinar, Drs. Emily Woodward and Max Vargas touched on the battle between these two objectives, among other access and reimbursement considerations, in the world of cell and gene therapy (CGT) development. CGT approaches seek to modify genetic … Continued

1 of 1
Powered by GlobalLink OneLink Software